Ravi Karia, MD enrolls first patient in trial use of an injectable antibiotic-eluting bone graft substitute

Raji Karia, MD

Lund, Sweden, 22 May 2017– BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery, today announced that the first patient has been enrolled by Dr Ravi Karia at the  University of Texas Health Science Center at San Antonio into the company’s pivotal Investigational Device Exemption (IDE) trial:  A Prospective, Randomized, Multicenter Controlled Trial of CERAMENT G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures (the FORTIFY trial: ClinicalTrials.gov Identifier: NCT02820363).

CERAMENT G is an injectable antibiotic-eluting bone graft substitute that has proven remodeling capabilities and provides local sustained delivery of gentamicin.  The data from the trial will support BONESUPPORT’s PMA (Premarket Approval) filing for CERAMENT G in the US.

Click here to see the full article on the Orthospinenews website.

X
X